This presentation argues that poetry (i.e., experimental uses of language) represents crucial data about the content of psychedelic experiences within the context of scientific research. I call for the need to develop psychedelic studies in the humanities, since the discourse of science is essential but insufficient for exploring these liminal realms of consciousness. Although the majority of recent work in psychedelic studies relies on quantitative, objectively verifiable measures, my research demonstrates that psychedelic science is frequently characterized by a necessary reliance on both science and poetry. The process of exploring non-ordinary states of consciousness depends upon the communication of unprecedented subjective experiences—a process that necessarily relies on metaphor and other creative uses of language, since no ready-made vocabulary exists to describe these experiences. For this reason, I argue that literary theory and poetic interpretation are as crucial as chemical analysis for generating data in psychedelic science and the scientific study of consciousness more generally. Drawing on my recent scholarship as a Research Fellow with the New York Public Library’s Timothy Leary Papers, I demonstrate that psychedelic scientists have theorized about the experimental value of poetic language since the first wave of psychedelic research in the twentieth century. I connect this lineage to the psychedelic renaissance based on my experiences as a Research Fellow with the NYU School of Medicine, where I joined four other co-authors in collaboratively analyzing patient transcripts for underlying themes. My presentation ends by proposing future directions for clinical research based on Neiloufar Family’s call at Breaking Convention 2015 for renewed scholarship on the relationships between psychedelics, neurochemistry, and language, and I argue that “trip reports” deserve further study as an established genre of literature.
NESE DEVENOT is an Andrew W. Mellon Postdoctoral Fellow in Digital Humanities at the University of Puget Sound, where she teaches classes on psychedelics and literature and is also working on her book project, “Chemical Poetics: The Literary History of Psychedelic Science.” In 2016 she was awarded “Best Humanities Publication in Psychedelic Studies” from Breaking Convention in the United Kingdom as part of their First Annual Psychedelic Research Awards. As a 2016 Cosmic Sister Women of the Psychedelic Renaissance grant recipient, she is working on a journalistic account of a fully-funded trip to ayahuasca retreat centers in the Peruvian Amazon. She was a 2015-16 Research Fellow at the New York Public Library’s Timothy Leary Papers and also a Research Fellow with the New York University Psilocybin Cancer Anxiety Study, where she participated in the first qualitative study of patient experiences. She received her PhD in 2015 from the Program in Comparative Literature and Literary Theory at the University of Pennsylvania, where she studied psychedelic philosophy and the literary history of chemical self-experimentation (“trip reports”). She taught the class “Drug Wars: The Influence of Psychoactive Rhetoric” as a 2014-15 Critical Speaking Fellow, and she was also a 2014-15 Andrew W. Mellon Graduate Research Fellow with the Penn Humanities Forum, where she worked on the project “‘Innumerable Fine Shades’: Psychedelics and Synesthesia in the Literary Self-Experiments of Aldous Huxley.” She is a founder of the Psychedemia interdisciplinary psychedelics conference, and the former editor of “This Week in Psychedelics,” a Reality Sandwich column that reported on psychedelic news in the media between 2011 and 2013. She was a founding member of the MAPS Graduate Student Association, which she moderated during 2011-13, and she has presented on psychedelics at numerous conferences in the United States, Canada, England, Australia, and the Netherlands. Her opinion articles about psychedelics and social justice have helped to inspire a psychedelic “coming out” movement in the United Kingdom.
Psychedelics are making their way back into mainstream science. High profile research teams are publishing findings in top journals showing that psychedelics can be used to better understand cognition, perception, neurobiology, psychopathology and wellbeing. At the same time there is increasing interest and acceptance of these substances amongst the general public. One topic of growing interest is the phenomenon of “microdosing” – taking extremely low doses of a psychedelic substance, most typically LSD or psilocybin. A microdose can be 1/10th or less of a recreational dose and users will often microdose regularly every 3 or 4 days over an extended period of time. Due to the very low dose, microdosers do not usually report the dramatic cognitive and perceptual changes that typically characterise psychedelic experiences, rather immediate effects are reported to be very subtle and sometimes barely noticeable. Despite this microdosers make a wide variety of claims for the benefits of microdosing, including improved vitality, positive mood, increased attention and greater creativity. Although microdosing has exploded in popularity in recent years, there has been very little empirical research on this topic and the accuracy of these claims has not been tested.
Our team conducted a systematic observational study of the effects of microdosing in healthy participants over the course of 6 weeks. Sixty regular microdosers provided baseline, daily, weekly, and post-study ratings of mood, attention, wellbeing, mindfulness, mystical experiences, personality, creativity and sense of agency. I’ll report what did and did not change for this group, talk about the role of placebo in the use of psychedelics, and try to answer the question of what really happens when people microdose.
VINCE POLITO is a postdoctoral research fellow at the Australian Research Council Centre of Excellence in Cognition and its Disorders at Macquarie University. His research aims to understand how self-monitoring changes in altered states of consciousness. To do this he has investigated attentional changes in meditation, psychiatric symptoms of disturbed control, states of flow in expertise, hypnotic suggestions, body representation alterations in virtual reality, and the effects of psychedelic substances.
The Australian Psychedelic Society are proud to support psychedelic comedian Shane Mauss’ Australian tour. We have two double passes to give away, one for Shane’s Sydney show and one for his Melbourne show. All you have to do to enter is scroll to the bottom of this page and put in your details.
We’ll announce the Melbourne winner on Monday the 16th of October and Sydney winner on Friday the 20th October. Make sure to enter your real full name for the door list and contact details so we can tell you if you’ve won.
Shane Mauss wants us all to have a good trip. Join him on a funny journey through the stigma, history, laws, and science of psychedelics when Shane brings his acclaimed comedy show about psychedelics, science and how they mesh to Australia this October.
His hilarious, thought-provoking, stand-up-storytelling comedy show will open your eyes to psychedelics in a new and truly unique way. Part stand-up, part storytelling, and part TED Talk combine for an informative and funny comedy show as Shane shares personal experiences and discusses the effects of hallucinogens such as mushrooms, LSD, and DMT.
Shane has played SXSW, guested on some of the world’s biggest comedy podcasts including You Made It Weird with Pete Holmes, WTF with Marc Maron, Duncan Trussell’s Family Hour, Ari Shaffir’s Skeptic Tank and Wil Anderson’s TOFOP, performed on TV everywhere from Conan to Jimmy Kimmel to Just For Laughs, has a Netflix special and has travelled across the US interviewing scientists about the meaning of life for his podcast Here We Are.
After a 100+ date tour of the USA Shane is ready to introduce A Good Trip to Australian audiences.
Thu 19 Oct – Sat 21 Oct (8.00pm)
Sat 28 Oct (7.15pm)
WIN A DOUBLE PASS TO SEE SHANE MAUSS ‘A GOOD TRIP’
The Australian Psychedelic Society (Sydney) is proud to present our first official screening of A New Understanding: The Science of Psilocybin as part of the 920 Coalition events. Held around the world each year on 20th September, the coalition is focused on research and the role that psychedelic psilocybin mushrooms play in our society and health care system.
A New Understanding explores the treatment of end-of-life anxiety in terminally ill cancer patients using psilocybin to facilitate deeply spiritual experiences as part of the first psychedelic research studies with terminally ill patients since the 1970s. The recent resurgence of psychedelic research is once again revealing the power of compounds like psilocybin to profoundly alter our understanding of both life and death in a society that devotes a great deal of attention to treating cancer, but very little to treating the human being who is dying of cancer.
Wednesday 20th September 2017
7:00 pm – 10:00 pm
342 Elizabeth Street
Find the others.